Short Interest in Marker Therapeutics, Inc. (NASDAQ:MRKR) Decreases By 46.4%

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a significant drop in short interest in June. As of June 30th, there was short interest totaling 116,653 shares, a drop of 46.4% from the June 15th total of 217,647 shares. Based on an average daily trading volume, of 52,848 shares, the days-to-cover ratio is presently 2.2 days. Currently, 0.7% of the company’s stock are sold short.

Marker Therapeutics Stock Performance

Marker Therapeutics stock opened at $1.44 on Wednesday. The firm’s 50-day moving average is $1.44 and its 200-day moving average is $1.52. Marker Therapeutics has a 1 year low of $0.81 and a 1 year high of $4.07. The company has a market cap of $24.00 million, a P/E ratio of -2.36 and a beta of 1.45.

Marker Therapeutics (NASDAQ:MRKR) last posted its earnings results on Friday, May 15th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company had revenue of $0.75 million during the quarter, compared to analyst estimates of $0.78 million. Marker Therapeutics had a negative return on equity of 73.29% and a negative net margin of 343.03%. As a group, sell-side analysts predict that Marker Therapeutics will post -1.17 earnings per share for the current year.

Institutional Trading of Marker Therapeutics

Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC increased its stake in shares of Marker Therapeutics by 41.8% in the first quarter. Renaissance Technologies LLC now owns 175,294 shares of the company’s stock valued at $228,000 after purchasing an additional 51,644 shares during the period. NewEdge Advisors LLC acquired a new position in Marker Therapeutics during the 4th quarter worth $222,000. XTX Topco Ltd increased its holdings in shares of Marker Therapeutics by 166.6% during the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after purchasing an additional 36,269 shares during the period. Osaic Holdings Inc. lifted its holdings in Marker Therapeutics by 16.5% in the fourth quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after purchasing an additional 13,340 shares during the period. Finally, Jane Street Group LLC bought a new stake in shares of Marker Therapeutics during the 4th quarter worth about $60,000. 22.39% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on MRKR shares. HC Wainwright restated a “buy” rating on shares of Marker Therapeutics in a research note on Wednesday, May 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Wednesday, June 24th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $10.00.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.